Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3706674 in Advanced Gastric and Oesophageal Cancer
NCT06056024Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of BI 3706674 in gastric adenocarcinoma, oesophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose Limiting Toxicities at 3.5 years, Adverse Events at 3.5 years and 1 more. Started Dec 2023; status: completed.
02
Drugs
BI 3706674
03
Conditions
gastric adenocarcinomaoesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06056024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06056024.